Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 13.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and GeneDx Holdings Corp for 19 Days on average.
| SHY | WGS | |
|---|---|---|
Market Cap | $26.68B | $2.02B |
Volume | 4,077,691 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $167.51 |
52-Week Low | $81.05 | $34.51 |
Typical Hold Time | 63 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.185 with minimal daily movement (+0.03%), reflecting stability amid broader bond market volatility. The technical picture shows a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend payments of $0.24-$0.25 demonstrate consistent income distribution. The fund operates in a challenging environment with rising Treasury yields impacting bond valuations.
SHY faces headwinds from the ongoing bond market selloff and rising interest rates, which pressure short-term bond ETFs. However, the fund's structure provides relative stability compared to longer-duration instruments. The primary risk remains further Fed tightening, while the opportunity lies in capital preservation during market turbulence.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
